Non Tuberculous Mycobacterial Infections Market Size is projected to grow at a significant CAGR by 2034

The Nontuberculous Mycobacterial (NTM) Infections Market size is projected to experience consistent expansion, maintaining a robust CAGR throughout the forecast period (2024–2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Non Tuberculous Mycobacterial Infections landscape.

The total Nontuberculous Mycobacterial (NTM) Infections Market size in the US was valued at around USD 360 million in 2023 and is expected to grow steadily throughout the forecast period (2024–2034).

According to DelveInsight’s analysis, ARIKAYCE held the largest share of the Nontuberculous Mycobacterial (NTM) Infections Market, generating around USD 223 million in revenue for refractory MAC cases in the US in 2023, with growth anticipated over the forecast period (2024–2034). In the same year, macrolides accounted for nearly USD 26 million, while ethambutol and rifamycin/rifampin each contributed approximately USD 16 million. Additionally, off-label therapies represented about USD 41 million of the US NTM infections market in 2023.

According to DelveInsight’s epidemiology estimates, the diagnosed prevalence of Nontuberculous Mycobacterial (NTM) Infections in the US was around 108,000 cases in 2023, a figure projected to rise throughout the forecast period (2024–2034) due to multiple contributing factors. Among species-specific cases, Mycobacterium avium represented the largest share, with nearly 76,000 diagnosed cases, followed by M. abscessus at around 14,000 cases, and other species such as M. kansasii and M. xenopi collectively accounting for approximately 18,000 cases.

In 2023, the United States reported around 86,000 diagnosed cases of pulmonary Nontuberculous Mycobacterial (NTM) infections and nearly 22,000 extrapulmonary cases. Among these, moderate cases were the most common, totaling approximately 58,000, followed by about 36,000 mild cases and 13,000 severe cases.

DelveInsight’s report “Non Tuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Non Tuberculous Mycobacterial Infections landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

The Non Tuberculous Mycobacterial Infections market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Non Tuberculous Mycobacterial Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non Tuberculous Mycobacterial Infections Market Forecast

Some of the key facts of the Non Tuberculous Mycobacterial Infections Market Report:

• The current treatment approach for Nontuberculous Mycobacterial (NTM) infections primarily involves combination antibiotic regimens, typically including macrolides, rifamycins, and ethambutol, among others.
• At present, ARIKAYCE (amikacin liposome inhalation suspension) remains the only FDA-approved therapy specifically indicated for Nontuberculous Mycobacterial (NTM) infections, marking a major advancement in inhalation-based treatment for adults with refractory disease.
• The treatment landscape for Nontuberculous Mycobacterial (NTM) infections is rapidly advancing with the development of innovative pipeline therapies such as NUZYRA (omadacycline) and Clofazimine Inhalation Suspension (MNKD-101). These emerging candidates offer novel therapeutic approaches aimed at addressing the substantial unmet needs in managing this complex disease.
• Key Non Tuberculous Mycobacterial Infections Companies: Vast Therapeutics, Crestone, Inc, Matinas BioPharma Holdings, Inc, LigaChemBio, Insmed, AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others 
• Key Non Tuberculous Mycobacterial Infections Therapies: ALX1, CRS0393, MAT2501, Delpazolid, ARIKAYCE (amikacin liposome inhalation suspension), Epetraborole, MNKD-101 (Clofazimine Inhalation Suspension), SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others

Non Tuberculous Mycobacterial Infections Overview

Non-Tuberculous Mycobacterial (NTM) Infections are caused by a group of mycobacteria species other than Mycobacterium tuberculosis and M. leprae. These bacteria are commonly found in soil, water, and the environment and can lead to infections in the lungs, skin, or other organs, especially in people with weakened immune systems or pre-existing lung conditions. Pulmonary NTM infections are the most common, causing chronic cough, fatigue, and respiratory issues. While not typically contagious between people, NTM infections can be challenging to treat due to their resistance to standard antibiotics.

Get a Free sample for the Non Tuberculous Mycobacterial Infections Market Report:

https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market

Key Trends in Non Tuberculous Mycobacterial Infections Therapeutics Market

• Development of Novel Antimicrobial Therapies: Increasing focus on new antibiotics and combination regimens to target resistant Non Tuberculous Mycobacterial Infections strains.
• Advancements in Diagnostic Technologies: Improved molecular diagnostics and rapid testing facilitating earlier detection and personalized treatment.
• Expansion of Clinical Trials: Rising number of global trials evaluating innovative drugs and multi-drug therapies for NTM infections.
• Shift Toward Personalized and Targeted Therapy: Use of pathogen-specific treatment strategies based on species identification and drug susceptibility profiles.
• Integration of Adjunctive and Supportive Treatments: Growing emphasis on therapies that improve lung function and patient quality of life alongside antimicrobial treatment.

Non Tuberculous Mycobacterial Infections Epidemiology

The Non Tuberculous Mycobacterial Infections epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034 It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non Tuberculous Mycobacterial Infections Epidemiology Segmentation:

The Non Tuberculous Mycobacterial Infections market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of NTM Infections in the 7MM
• Total Diagnosed Prevalent Cases of NTM Infections in the 7MM
• Gender-specific Diagnosed Prevalent Cases of NTM Infections in the 7MM
• Species-specific Diagnosed Prevalent Cases of NTM Infections in the 7MM
• Type-specific Diagnosed Prevalent Cases of NTM Infections in the 7MM
• Severity-specific Diagnosed Prevalent Cases of NTM Infections in the 7MM
• Treatable Cases of NTM Infections in the 7MM

Download the report to understand which factors are driving Non Tuberculous Mycobacterial Infections epidemiology trends @ Non Tuberculous Mycobacterial Infections Epidemiological Insights

Recent Developments In The Non Tuberculous Mycobacterial Infections Treatment Landscape:

• In January 2025, Shanghai MicuRx Pharmaceutical Co. Ltd. reported that its anti-infection drug, MRX-5, has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for treating non-tuberculous mycobacteria (NTM) infections.
• In December 2024, Shanghai MicuRx Pharmaceutical (688373.SH) announced that the FDA has granted Orphan Drug Designation (ODD) to its anti-infection drug, MRX-5, for treating non-tuberculous mycobacteria (NTM) infections, marking a key milestone in advancing NTM therapy.
• In October 2024, Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company developing novel therapies for rare diseases and multidrug-resistant (MDR) bacterial infections, announced the publication of results from its Phase 1 clinical trial evaluating the intrapulmonary pharmacokinetics (PK) of SPR719. The full study, titled “Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers,” was published ahead of print in Antimicrobial Agents and Chemotherapy.
• In November 2024, Paratek Pharmaceuticals announced positive topline results from its Phase IIb clinical trial assessing the oral antibiotic Nuzyra (omadacycline) in adult patients with nontuberculous mycobacterial (NTM) pulmonary disease.
• In October 2024, Shanghai MicuRx Pharmaceutical Co., Ltd. announced the successful completion of a Phase I clinical trial in Australia for MRX-5, its self-developed oral antibacterial candidate aimed at treating nontuberculous mycobacterial (NTM) infections. 

Non Tuberculous Mycobacterial Infections Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non Tuberculous Mycobacterial Infections market or expected to get launched during the study period. The analysis covers Non Tuberculous Mycobacterial Infections market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non Tuberculous Mycobacterial Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non Tuberculous Mycobacterial Infections Therapies and Key Companies

• Clofazimine Inhalation Suspension (MNKD-101): MannKind
• NUZYRA (omadacycline): Paratek Pharmaceuticals
• ALX1: Vast Therapeutics
• CRS0393: Crestone, Inc.
• MAT2501: Matinas BioPharma Holdings, Inc
• Delpazolid: LigaChemBio
• ARIKAYCE (amikacin liposome inhalation suspension): Insmed
• Epetraborole: AN2 Therapeutics
• MNKD-101 (Clofazimine Inhalation Suspension): Mannkind Corporation
• SPR720: Spero Therapeutics
• Molgramostim: Savara Pharmaceuticals
• Thiolanox (Nitric Oxide): Mallinckrodt Inc.
• NUZYRA (omadacycline): Paratek Pharmaceuticals Inc.
• CYT 107: Revimmune

To know more about Non Tuberculous Mycobacterial Infections treatment, visit @ Non Tuberculous Mycobacterial Infections Medications

Non Tuberculous Mycobacterial Infections Market Drivers

• Rising Prevalence of NTM Infections: Increasing cases globally, particularly among immunocompromised patients and those with chronic lung diseases.
• Advancements in Diagnostic Tools: Improved molecular diagnostics and culture techniques enable early detection and accurate species identification.
• Growing Awareness Among Healthcare Professionals: Better recognition of NTM infections supports timely treatment initiation.
• Development of Novel Therapeutics: Introduction of new antibiotics, combination regimens, and targeted therapies is driving market growth.
• Expansion of Clinical Research: Rising clinical trials and R&D efforts focused on effective and safer treatment options.

Non Tuberculous Mycobacterial Infections Market Barriers

• Complex and Prolonged Treatment Regimens: Multi-drug therapies over extended periods lead to poor patient adherence.
• High Drug Resistance: Resistance among NTM strains limits the effectiveness of existing antibiotics.
• Limited Awareness in General Population: Lack of patient knowledge delays diagnosis and treatment.
• High Treatment Costs: Long-term therapy and specialized care increase financial burden.
• Regulatory and Reimbursement Challenges: Difficulties in drug approval and limited insurance coverage may hinder market expansion.

Scope of the Non Tuberculous Mycobacterial Infections Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Non Tuberculous Mycobacterial Infections Companies: Vast Therapeutics, Crestone, Inc, Matinas BioPharma Holdings, Inc, LigaChemBio, Insmed, AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others
• Key Non Tuberculous Mycobacterial Infections Therapies: ALX1, CRS0393, MAT2501, Delpazolid, ARIKAYCE (amikacin liposome inhalation suspension), Epetraborole, MNKD-101 (Clofazimine Inhalation Suspension), SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others
• Non Tuberculous Mycobacterial Infections Therapeutic Assessment: Non Tuberculous Mycobacterial Infections current marketed and Non Tuberculous Mycobacterial Infections emerging therapies
• Non Tuberculous Mycobacterial Infections Market Dynamics: Non Tuberculous Mycobacterial Infections market drivers and Non Tuberculous Mycobacterial Infections market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Non Tuberculous Mycobacterial Infections Unmet Needs, KOL’s views, Analyst’s views, Non Tuberculous Mycobacterial Infections Market Access and Reimbursement 

Discover more about therapies set to grab major Non Tuberculous Mycobacterial Infections market share @ Non Tuberculous Mycobacterial Infections Treatment Landscape